Related Experiment Video

Updated: Jan 6, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

54.3K

Hepatobiliary manifestations of inflammatory bowel disease in children

Magdalena Kucharska1, Urszula Daniluk1, Kamila Agnieszka Kwiatek-Średzińska1

  • 1Department of Pediatrics, Gastroenterology, Hepatology, Nutrition and Allergology, Medical University of Bialystok, Poland.

Clinical and Experimental Hepatology
|October 11, 2019
PubMed

Insights

Pediatric inflammatory bowel disease (IBD) can involve liver and bile duct issues. This review covers current literature on these hepatobiliary manifestations in children with IBD.

Area of Science:

  • Pediatric Gastroenterology
  • Hepatology
  • Immunology

Background:

  • Inflammatory bowel disease (IBD) presents diagnostic and therapeutic challenges in pediatrics.
  • Extraintestinal manifestations (EIMs) complicate IBD management, particularly hepatobiliary conditions.
  • Early recognition of hepatobiliary complications is crucial for optimal pediatric IBD care.

Purpose of the Study:

  • To review the current literature on hepatobiliary manifestations in pediatric inflammatory bowel disease.
  • To provide an overview of the spectrum of liver and bile duct conditions associated with IBD in children.
  • To highlight diagnostic and therapeutic considerations for pediatric hepatobiliary IBD.

Main Methods:

  • Systematic literature review.
  • Analysis of current research on pediatric IBD and hepatobiliary complications.
  • Synthesis of findings from relevant studies.

Main Results:

  • Hepatobiliary manifestations are significant EIMs in pediatric IBD.
  • Commonly reported conditions include primary sclerosing cholangitis, autoimmune hepatitis, and fatty liver disease.
  • The review details the epidemiology, clinical presentation, and management strategies for these conditions.

Conclusions:

  • Hepatobiliary involvement is a critical aspect of pediatric IBD.
  • Pediatricians must be vigilant for these manifestations to ensure comprehensive patient care.
  • Further research is needed to elucidate pathogenesis and optimize treatment protocols.

Keywords:
Crohn’s diseasechildrenhepatobiliary manifestationsinflammatory bowel diseaseulcerative colitis

More Related Videos

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

3.2K
Chronic Salmonella Infection Induced Intestinal Fibrosis08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.5K

Related Concept Videos

Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
833
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
716
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
898
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
420
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
596
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
424